• NICE to reassess Kyowa Kirin’s Poteligeo pharmatimes
    June 16, 2021
    The National Institute for Health and Care Excellence (NICE) will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by the companies and various charities.
PharmaSources Customer Service